3-[(1S,4R,5R,8S,9S,12S,13R)-13-ethyl-5-[(E,2R)-6-hydroperoxy-6-methylhept-4-en-2-yl]-4,8-dimethyl-12-tetracyclo[7.5.0.01,13.04,8]tetradecanyl]but-3-eneperoxoic acid
| Internal ID | d624a8d1-9731-42ee-94e8-8424d6176ddb |
| Taxonomy | Lipids and lipid-like molecules > Prenol lipids > Triterpenoids |
| IUPAC Name | 3-[(1S,4R,5R,8S,9S,12S,13R)-13-ethyl-5-[(E,2R)-6-hydroperoxy-6-methylhept-4-en-2-yl]-4,8-dimethyl-12-tetracyclo[7.5.0.01,13.04,8]tetradecanyl]but-3-eneperoxoic acid |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C30H48O5/c1-8-29-19-30(29)17-16-27(6)22(20(2)10-9-14-26(4,5)35-33)13-15-28(27,7)24(30)12-11-23(29)21(3)18-25(31)34-32/h9,14,20,22-24,32-33H,3,8,10-13,15-19H2,1-2,4-7H3/b14-9+/t20-,22-,23+,24+,27-,28+,29-,30+/m1/s1 |
| InChI Key | QKZQYIBFNDGESI-YBJPUULCSA-N |
| Popularity | 2 references in papers |
| Molecular Formula | C30H48O5 |
| Molecular Weight | 488.70 g/mol |
| Exact Mass | 488.35017463 g/mol |
| Topological Polar Surface Area (TPSA) | 76.00 Ų |
| XlogP | 8.20 |
| Atomic LogP (AlogP) | 7.83 |
| H-Bond Acceptor | 5 |
| H-Bond Donor | 2 |
| Rotatable Bonds | 9 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.9863 | 98.63% |
| Caco-2 | - | 0.6647 | 66.47% |
| Blood Brain Barrier | + | 0.7000 | 70.00% |
| Human oral bioavailability | + | 0.5714 | 57.14% |
| Subcellular localzation | Mitochondria | 0.5191 | 51.91% |
| OATP2B1 inhibitior | - | 0.7115 | 71.15% |
| OATP1B1 inhibitior | + | 0.8291 | 82.91% |
| OATP1B3 inhibitior | + | 0.8999 | 89.99% |
| MATE1 inhibitior | - | 0.9600 | 96.00% |
| OCT2 inhibitior | - | 0.7750 | 77.50% |
| BSEP inhibitior | + | 0.7911 | 79.11% |
| P-glycoprotein inhibitior | + | 0.6175 | 61.75% |
| P-glycoprotein substrate | + | 0.5673 | 56.73% |
| CYP3A4 substrate | + | 0.6888 | 68.88% |
| CYP2C9 substrate | - | 1.0000 | 100.00% |
| CYP2D6 substrate | - | 0.8434 | 84.34% |
| CYP3A4 inhibition | - | 0.5564 | 55.64% |
| CYP2C9 inhibition | - | 0.6324 | 63.24% |
| CYP2C19 inhibition | - | 0.7215 | 72.15% |
| CYP2D6 inhibition | - | 0.9035 | 90.35% |
| CYP1A2 inhibition | - | 0.7523 | 75.23% |
| CYP2C8 inhibition | + | 0.5729 | 57.29% |
| CYP inhibitory promiscuity | - | 0.5643 | 56.43% |
| UGT catelyzed | - | 0.5000 | 50.00% |
| Carcinogenicity (binary) | - | 0.7300 | 73.00% |
| Carcinogenicity (trinary) | Non-required | 0.6484 | 64.84% |
| Eye corrosion | - | 0.9800 | 98.00% |
| Eye irritation | - | 0.9252 | 92.52% |
| Skin irritation | - | 0.6805 | 68.05% |
| Skin corrosion | - | 0.9257 | 92.57% |
| Ames mutagenesis | - | 0.5037 | 50.37% |
| Human Ether-a-go-go-Related Gene inhibition | - | 0.3717 | 37.17% |
| Micronuclear | - | 0.7400 | 74.00% |
| Hepatotoxicity | + | 0.5250 | 52.50% |
| skin sensitisation | - | 0.6592 | 65.92% |
| Respiratory toxicity | - | 0.5444 | 54.44% |
| Reproductive toxicity | + | 0.6444 | 64.44% |
| Mitochondrial toxicity | + | 0.6500 | 65.00% |
| Nephrotoxicity | - | 0.5860 | 58.60% |
| Acute Oral Toxicity (c) | III | 0.5244 | 52.44% |
| Estrogen receptor binding | + | 0.6779 | 67.79% |
| Androgen receptor binding | + | 0.7223 | 72.23% |
| Thyroid receptor binding | + | 0.6096 | 60.96% |
| Glucocorticoid receptor binding | + | 0.7463 | 74.63% |
| Aromatase binding | + | 0.7788 | 77.88% |
| PPAR gamma | + | 0.5201 | 52.01% |
| Honey bee toxicity | - | 0.6954 | 69.54% |
| Biodegradation | - | 0.8250 | 82.50% |
| Crustacea aquatic toxicity | - | 0.6500 | 65.00% |
| Fish aquatic toxicity | + | 1.0000 | 100.00% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL240 | Q12809 | HERG | 99.67% | 89.76% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 98.07% | 97.25% |
| CHEMBL218 | P21554 | Cannabinoid CB1 receptor | 97.85% | 96.61% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 97.32% | 96.09% |
| CHEMBL4005 | P42336 | PI3-kinase p110-alpha subunit | 95.72% | 97.47% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 94.49% | 91.11% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 94.19% | 94.45% |
| CHEMBL4246 | P42680 | Tyrosine-protein kinase TEC | 93.57% | 82.05% |
| CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 93.23% | 91.03% |
| CHEMBL4793 | Q86TI2 | Dipeptidyl peptidase IX | 93.13% | 96.95% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 92.98% | 95.71% |
| CHEMBL1293267 | Q9HC97 | G-protein coupled receptor 35 | 92.71% | 89.34% |
| CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 91.67% | 91.24% |
| CHEMBL233 | P35372 | Mu opioid receptor | 90.97% | 97.93% |
| CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 89.98% | 96.38% |
| CHEMBL2179 | P04062 | Beta-glucocerebrosidase | 89.16% | 85.31% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 89.12% | 100.00% |
| CHEMBL2581 | P07339 | Cathepsin D | 88.27% | 98.95% |
| CHEMBL1293316 | Q9HBX9 | Relaxin receptor 1 | 86.69% | 82.50% |
| CHEMBL340 | P08684 | Cytochrome P450 3A4 | 86.11% | 91.19% |
| CHEMBL284 | P27487 | Dipeptidyl peptidase IV | 86.02% | 95.69% |
| CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 85.51% | 94.33% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 85.47% | 93.56% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 85.29% | 95.89% |
| CHEMBL2955 | O95136 | Sphingosine 1-phosphate receptor Edg-5 | 85.07% | 92.86% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 84.82% | 92.88% |
| CHEMBL2007 | P16234 | Platelet-derived growth factor receptor alpha | 84.57% | 91.07% |
| CHEMBL5888 | Q99558 | Mitogen-activated protein kinase kinase kinase 14 | 84.56% | 100.00% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 84.20% | 96.47% |
| CHEMBL4051 | P13569 | Cystic fibrosis transmembrane conductance regulator | 83.57% | 95.71% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 83.22% | 100.00% |
| CHEMBL5600 | P27448 | Serine/threonine-protein kinase c-TAK1 | 83.15% | 88.81% |
| CHEMBL1841 | P06241 | Tyrosine-protein kinase FYN | 83.11% | 81.29% |
| CHEMBL2996 | Q05655 | Protein kinase C delta | 82.96% | 97.79% |
| CHEMBL2413 | P32246 | C-C chemokine receptor type 1 | 82.94% | 89.50% |
| CHEMBL3437 | Q16853 | Amine oxidase, copper containing | 82.91% | 94.00% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 82.67% | 97.09% |
| CHEMBL3145 | P42338 | PI3-kinase p110-beta subunit | 82.23% | 98.75% |
| CHEMBL3055 | P50613 | Cyclin-dependent kinase 7 | 82.09% | 81.88% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 81.81% | 95.89% |
| CHEMBL2373 | P21730 | C5a anaphylatoxin chemotactic receptor | 81.51% | 92.62% |
| CHEMBL3430907 | Q96GD4 | Aurora kinase B/Inner centromere protein | 80.94% | 97.50% |
| CHEMBL5251 | Q06187 | Tyrosine-protein kinase BTK | 80.83% | 98.51% |
| CHEMBL5028 | O14672 | ADAM10 | 80.47% | 97.50% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| Kadsura coccinea |
| PubChem | 100923237 |
| LOTUS | LTS0139171 |
| wikiData | Q105223435 |